74936-73-5

Basic information

• Product Name: BAY-M 5579
• CAS NO: 74936-73-5
• Molecular Weight: 346.34
• Mol File: 74936-73-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: BAY-M 5579(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-M 5579(74936-73-5)
• EPA Substance Registry System: BAY-M 5579(74936-73-5)

Safety Data

• Hazardous Substances Data: 74936-73-5(Hazardous Substances Data)

Usage

General Description

BAY-M 5579 is a chemical compound that is a potent inhibitor of the enzyme protease. It belongs to the class of peptidyl pyrazole derivatives and has been studied for its potential use in pharmaceuticals. It has been shown to be effective in inhibiting the replication of the hepatitis C virus and has promising antiviral properties. BAY-M 5579 has also been found to have inhibitory effects on other proteases, making it a versatile compound with potential therapeutic applications in various diseases. Further research is ongoing to fully understand its mechanism of action and potential uses in medical treatments.

Upstream product

• 626-34-6 ethyl aminocrotonate 
• 102993-38-4 2-cyanoethyl 2-(3-nitrobenzylidene)-3-oxobutanoate 
• 141-97-9 ethyl acetoacetate 
• 39562-16-8 ethyl 2-(3-nitrophenylmethylene)-3-oxobutanoate 
• 99-61-6 3-nitro-benzaldehyde 
• 75130-25-5 3-(2-cyanoethyl) 5-ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 

Downstream Products

• 439694-61-8 (R)-5-(ethoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 

Relevant articles and documents

Compound and its as L-type calcium channel blocker or/and application of acetylcholine esterase inhibitors

Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.

1,4-dihydropyridine derivatives

1,4-Dihydropyridine derivatives of formula: STR1 wherein Ar1 represents an aromatic hydrocarbon group or an aromatic heteromonocyclic or heterobicyclic group containing therein 1 to 3 atoms selected from the group consisting of oxygen, sulfur and nitrogen; R1 represents a hydrocarbon group which may have one or more substituents; A represents (i) a straight chain or branched chain unsaturated hydrocarbon group, (ii) a cyclic unsaturated hydrocarbon group, or (iii) a group selected from the group consisting of --R--O--N=CH--, --R--N=N--, --R--CH=N-- and --R--N=CH--, in which R is an alkylene group having 1 to 6 carbon atoms; B represents an alkylene or alkenylene group having 1 to 3 carbon atoms, which may have a substituent; Ar2 represents an aromatic hydrocarbon group or a heterocyclic group; Ar3 represents a heterocyclic group which may have one or more substituents; and n is 0 or 1, and the corresponding optical active 1,4-dihydropyridine derivatives, having an optically active cite as indicated by *, have both superior vasodilative and platelet aggregation inhibiting activities.

Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing a nitrooxy moiety at the 3-ester position

The synthesis of a new series of dihydropyridines containing a nitrooxy moiety at the 3-ester position is described. The antihypertensive activity of the compounds was examined and compared with that of nifedipine; some of them were relatively potent. The structure-activity relationship is also discussed.